Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Novel immunotherapeutic strategies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen -4 blockade in advanced melanoma Melanoma Res 2010 (in press)
2. 2010 Everolimus (RAD 001) in the treatment of advanced renal cell carcinoma The Oncolgist March 2010 (in press)
3. 2009 Chemoablation of melanoma with intralesional rose Bengal (PV-10) Journal Clin Oncol 476s, abstr 9060, 2009
4. 2009 Current Systemic Therapy for Metastatic Melanoma Expert Rev Anticancer Ther 9(5) 587-595, 2009
5. 2009 Implications of chemotherapy-biotherapy in the treatment of metastatic melanoma From Local Invasion to Metastatic Cancer. Leong S (ed) Humana Press 2009
6. 2009 Adjuvant therapy for malignant melanoma – Targeted pathways to antitumor potential and better outcomes Amer J Hematology/Oncology Suppl 2009.
7. 2009 Duration of high-dose interferon alfa2b regimen for resected high-risk melanoma Journal Clin Oncol 27
8. 2009 Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms Journal Clin Oncol 27: 1235-1242
9. 2009 LDH correlation with survival in advanced melanoma from two large randomized trials (Oblimersen GM301 and EORTC 18951). Europan Journal of Cancer 45: 1807-1814
10. 2009 A Phase II trial of Fosbretabulin in advanced anaplastic thyroid carcinoma Thyroid 19: 233-240, 2009
11. 2009 A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinome and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome Thyroid 19:2009, 233-240
12. 2009 Adjuvant therapy of melanoma Amer J Hematol Oncol 8(5) 256-258, 2009
13. 2008 Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma Cancer 2008;112(5):1131-8
14. 2008 Eggermont: Prognostic impact of baseline LDH on survival independent of tumor burden in advanced melanoma: Results of phase III trial of oblimersen-dacarbazine (OBL-DTIC) vs DTIC Clin Oncol 26: 2008 (May 20 suppl; abstr 20007)
15. 2008 Novel agents changing the outlook for renal cell carcinoma Community Oncology April 2008
16. 2008 Melanoma Vaccines Expert Rev Vaccines 7(7) 937-949, 2008
17. 2008 A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer Investigational new drugs 2008;26(2):183-8.
18. 2008 Integrated safety analysis of elesclomol (formerly STA-4783) co-administered with paclitaxel J Clin Oncol 26: 2008 (May 20 suppl; abstr 14595)
19. 2008 Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008;26(12):2034-9
20. 2008 Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer Laryngoscope 2008;118(3):444-9.
21. 2007 A phase II study of arsenic trioxide (ATO) in patients with metastatic melanoma Journal of Clinical Oncology 25(18S): 489s, Abstract 8569
22. 2007 Randomizied phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma Journal of Clinical Oncology 25(18S): 474s, Abstract 8510,
23. 2007 Phase III randomizied trial of postoperative radiotherapy (RT) with or without carboplatin (cb) in patients (pts) with head and neck squamous cell carcinoma (HNSCC) Journal of Clinical Oncology 25(18S): 318s
24. 2007 Long-term outcomes with concurrent carboplatin, paclitaxel, and radiation therapy in locally advanced, inoperable head and neck cancer Journal of Clinical Oncology 25(18S): 307s, Abstract 6032,
25. 2007 Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers Clin Cancer Res 1769 2007;13(6)March 15
26. 2007 Durable Complete Responses With High-Dose Bolus Interleukin-2 in Patients With Metastatic Melanoma Who Have Experienced Progression After Biochemotherapy J Clin Oncol 2007;25(25):3802-7
27. 2007 Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. 1.      N Engl J Med. 2007 Oct 25;357(17):1705-15
28. 2007 Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group J Clin Oncol 26(13): 2178-85
29. 2007 An Overview of New and Existing Therapies for Metastatic Melanoma Oncology Issues 22(4) 18-21, 2007
30. 2006 Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HDB) IL-2 in patients with metastatic melanoma Proc Am Soc Clin Oncol 24:18S
31. 2006 Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). Proc Am Soc Clin Oncol 24:291s
32. 2006 Interleukin-21 (IL-21): Tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma (MM) or renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 24:101s
33. 2006 Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). Proc Am Soc Clin Oncol 24300s
34. 2006 Targeting Growth Factors and Angiogenesis; Using Small Molecules in Malignancy Cancer Metastases Rev 25: 279-292
35. 2006 Molecularly Targeted Therapy for Melanoma: Current Prospects and Future Options Cancer 107: 2317-2327
36. 2006 Trends in Melanoma The American Journal of Hematology/Oncology 5(10):594-595; 2006
37. 2006 Cutaneous melanoma: available therapy for metastatic disease Dermatol Ther, 2006. 19(1): p. 19-25
38. 2006 Haluska, Oblimersen in Melanoma Update: Long-Term follow-Up Cancer Invest. 24(S2): 1
39. 2006 Sorafenib, a Pluripotent Molecule 3rd Meeting of the European Association of Dermato-Oncology, Rome, Italy. June 2006. J Invest Derm 126:S1
40. 2005 Phase II Trial of Sequential Temozolomide Chemotherapy Followed by High-dose Bolus IL-2 Immunotherapy for Metastatic Melanoma Proc Am Soc Clin Oncol 23:722s
41. 2005 Reply to letter to the editor regarding “Treatment of Brain Metastases from Melanoma” Journal of Clinical Oncology 23:3155-56
42. 2005 Novel agents in development for the treatment of melanoma Expert Opinion of Investigational Drugs 14:885-892
43. 2005 Long-Term Survivors after Gamma Knife Radiosurgery for Brain Metastases. Cancer 104:2784-2791
44. 2005 Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers. Clin Cancer Res 11:1-5
45. 2005 Radiosurgery for the Treatment of Spinal melanoma Metastases. Sterotact Funct Neurosurg 83:213-21
46. 2005 Phase I Study (Twice Weekly Schedule) of 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced refractory tumors Proc Am Soc Clin Oncol 23:204s
47. 2004 Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report Int Jrad Oncol Bio Phy. 60(5):1419-24
48. 2004 Mature Results of a Phase III Randomized Trial of Bacillus Calmette-Guerin (BCG) versus Observation and BCG plus Dacarbazine versus BCG in the Adjuvant Therapy of American Joint Committee on Cancer Stage I-III Melanoma (E1673). Cancer 100(8):1692-98;2004
49. 2004 Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck. J Clin Oncol 22(1):77-85
50. 2004 Phase I-II vaccine trial with MHC class II and MHC class I epitopes from Melan-A/MART-1 for patients with metastatic melanoma Proc Am Soc Clin Oncol 23:169;
51. 2004 A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17demethoxygeldanamycin (17AAG), NSC-704057) in patients with advanced tumors Proc Am Soc Clin Oncol 23:202
52. 2004 Phase II trial of high-dose bolus IL-2 in patients with metastatic melanoma (mm) who have previously failed biochemotherapy (BCT). Proc Am Soc Clin Oncol 23:709
53. 2004 Low-Dose Cytokine Therapy in the Adjuvant Treatment of High-Risk Melanoma—Another Negative Trial The American Journal of Oncology Review 3(4):217-20, 2004
54. 2004 A Patient with Recurrent Melanoma after Adjuvant Interferon Alfa Treated with High-Dose Interleukin-2 Case Studies in Oncology 6(4):3-7, 2004
55. 2004 Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis Immunotherapy 53:840-41;2004
56. 2004 Histamine and Low-Dose Aldesleukin: Overview and Results from US Trials Immune Modulation in Advanced Melanoma. pp10-12;2004
57. 2004 Brachytherapy in the treatment of Stage IV carcinoma of the base of tongue Brachytheray
58. 2004 Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study J Clin Oncol ; 22(11):2101-7
59. 2004 Management of brain metastases in patients with melanoma Curr Opin Oncol 16:161-66
60. 2004 Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors Clinical Cancer Research 10:2058-5064
61. 2003 UPCI 99-088: A phase I-II trial of vaccination against the novel MHC class II epitope Melan-A/MART-1 (M51-73) for metastatic melanoma: initial immunological and clinical results. Proc Am Soc Clin Oncol 22:721
62. 2003 Post-adjuvant (salvage) therapy of high-risk melanoma patients following the intergroup E1694 trial Proc Am Soc Clin Oncol. 22:720
63. 2003 Phase II trial of high-dose bolus IL-2 in patients with metastatic melanoma (mm) who have previously failed biochemotherapy (BCT). Proc Am Soc Clin Oncol. 22;724
64. 2003 Interferons and Adjuvant Therapy Cutaneous Melanoma. (fourth edition) Charles Balch, MD, Alan N. Houghton, MD, Arthur J, Sober, MD, Senj-jaw Soong, PhD(eds). Pp. 605-622
65. 2003 Epidemiology of Melanoma Cutaneous Melanoma Giuseppe Noto, Ed. Avantgarde. pp.11-16
66. 2003 Review of Complete Resection of Distant Metastases and Active Immunotherapy: A New Paradigm for the Management of Metastatic Melanoma. The American Journal of Oncology Review 2(2):77-79, 2003
67. 2003 New Interleukin-2-Containing Regimens for Treatment of High-Risk and Metastatic Melanoma Biological Therapy of Cancer 1(2):7-10
68. 2003 Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study Cancer 97(1):121-7
69. 2002 Pharmacokinetics of Histamine Dihydrochloride in Healthy Volunteers and Cancer Patients: Implications for Combined Immunotherapy with Interleukin-2 J Clin Pharmacol 42(7):774-781
70. 2002 Results from a Randomized Phase III Study Comparing Combined Treatment with Dihydrochloride plus Interleukin-2 versus Interleukin-2 Alone in Patients with Metastatic Melanoma. Journal of Clinical Oncology. 20(1):125-133
71. 2002 Phase II study of concurrent carboplatin/paclitaxel and radiation therapy (RT) in patients (pts) with locally advanced inoperable head and neck squamous cell carcinoma (HNSCC) Proc Am Soc Clin Oncol. 21:240a
72. 2002 Immunomodulatory effects of combination therapy with histamine dihyrochloride (HDC) and Interleukin-2 (IL-2) in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol. 21:343a
73. 2002 Cancer with Distant Metastasis Making in Ear, Nose, and Throat Disorders. Cuneyt M. Alper, MD; Eugene N. Myers, MD.; David E. Eibling, MD (eds) W.B. Saunders Company, pp 370-371
74. 2002 Update on adjuvant interferon therapy for high-risk melanoma Oncology 16(9): 1177-87, 2002
75. 2002 New Applications of Cancer Immunotherapy Seminars in Oncology 29(3):1-4, 2002
76. 2002 Intermediate- and High-risk Melanoma Current Treatment Options in Oncology 3:205-217, 2002
77. 2002 Melanoma: Epidemiology Encyclopedia of Cancer, Second Edition Vol 3. Joweph R. Bertino (ed. In chief) Academic Press, pp153-166
78. 2002 Histamine dihydrocholoride (HDC) administered with interleukin-2 (IL-2) increases survival duration in patients with AJCC stage M1c melanoma. Proc Am Soc Clin Oncol. 21:342a
79. 2002 Interleukin-2 and histamine dihydrochloride in metastatic melanoma. J Clin Oncol 20(16):3558-9,
80. 2002 mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy J Clin Oncol 20(17):3703-18
81. 2001 Cytokines Outline of Oncology Therapeutics. Mark J. Ratain, MD; Margaret Tempero, MD and Consuelo Skosey, RN, CCRA (eds) W.B. Saunders Company, pp 81-84
82. 2001 A solid platform for the development of future vaccines, and a modality that is under evolution for improved tolerance and improved efficacy with vaccines and chemotherapy. Melanoma Research 11(1):S40;
83. 2001 Dacarbazine, tamoxifen, alpha-IFN and IL-2 combinations: are they more effective? Melanoma Research 11(1):S47
84. 2001 Combined treatment with histamine dihydrochloride plus interleukin-2 improves survival compared to interleukin-2 alone in patients with metastatic melanoma: A randomized phase III study Melanoma Research 11(1):S64
85. 2001 The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared to interleukin-2 alone in patients with metastatic melanoma Melanoma Research 11(1):S124
86. 2001 High-dose Interferon alfa-2b Does not Dimish Antibody Response to GM2 Vaccination, and Improves Relapse-free Survival of Patients with Resectable Very-High Risk Melanoma: Results of the Multicenter ECOG Trial E2696. Journal of Clinical Oncology 19:1430-36; 2001
87. 2001 High-Dose Interferon Alfa-2b Significantly Prolonged Relapse-Free and Overall Survival Compared with the GM2-KLH/QS-21 Vaccine in Patients with Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801 Journal of Clinical Oncology 19:2370-80
88. 2001 Burden of Illness Associated with Metastatic Melanoma: An Audit of 100 Consecutive Referral Center Cases Cancer 91(9):1814-21;2001
89. 2001 The University of Pittsburgh Cancer Institute (UPCI) Experience with Interleukin-2 (IL-2) in the Treatment of Melanoma Immune Enhancing Cytokines 3(2):3-7, 2001
90. 2001 Chemotherapy Foundation Symposium XVIII: Session on Malignant Melanoma Meeting Highlights Exp Opin Invest Drugs 10(2):381-385; 2001
91. 2001 Phase I, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer Cytokines, Cellular & Molecular Therapy 6:171-176
92. 2001 Histamine dihydrochloride: inhibiting oxidants and synergising IL-2 mediated immune activation in the tumour microenviroment Exp Opin Biol Ther 1(5):869-879;2001.
93. 2001 A Phase I/II Trial of Escalating Doses of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Head & Neck Cancer (HNC) Patients Receiving Radiotherapy (RT) with Concurrent Chemotherapy (CCT). Proc of Ame Soc Thera Rad Oncol 51(3):40;
94. 2001 Safety profile of histamine dihydrochloride administered with interleukin-2 in patients with advanced metastatic malignant melanoma. Proc Am Soc Clin Oncol.37(6):S80
95. 2001 Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases. Proc Am Soc Clin Oncol. 37(6):S33
96. 2001 Efficacy evaluable subset analysis of a multicenter, randomized phase III study of histamine dihydrochloride plus interleukin-2 (IL-2) versus IL-2 alone in patients with stage IV malignant melanoma Melanoma Research 11(1):S195
97. 2001 Chemotherapy of Head and Neck Cancer Decision Making in Ear, Nose, and Throat Disorders. Cuneyt M. Alper, MD; Eugene N. Myers, MD.; David E. Eibling, MD (eds) W.B. Saunders Company, pp 362-363
98. 2000 Phase II Study of Weekly Carboplatin and Paclitaxel Concurrent with Radiation Therapy (RT) in Patients (Pts) with Locally Advanced, Inoperative Squamous Cell Carcinoma of the Head and Neck (HNSCC). Proc Amer Soc Clin Oncol 19:1667
99. 2000 Multi-Center Phase III Study of Histamine Dihydrochloride (MaxamineÔ) Plus Interleukin-2 (IL-2) versus IL-2 Alone in Patients with Metastatic Melanoma (MM): A Single-Center Interim Analysis Proc Amer Soc Clin Oncol 19:2252a, 2000
100. 2000 Biologic Therapy Clinics in Plastic Surgery. 27(4):643-665
101. 2000 Post Hoc Economic Analysis of Temozolomide Versus Dacarbazine in the Treatment of Advanced Metastatic Melanoma Journal of Clinical Oncology 18(7):1474-1480
102. 2000 Update on the role of adjuvant interferon for high risk melanoma. Forum 3:230-239; 2000
103. 2000 Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma. The Oncologist 5:144-51; 2000
104. 2000 Interferon in Epithelial Cancers Biologic Therapy of Cancer, (third edition) Steven Rosenberg, MD (ed), Lippincott, Williams & Wilkins, pp 275-285
105. 2000 Adjuvant Therapy of Melanoma Strategies in Adjuvant Therapy John M. Kirkwood (ed.), Martin Dunitz, pp 93-103
106. 2000 Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials Proc Amer Soc Clin Oncol 19:2171; 2000
107. 2000 Results of a randomized, multicenter, phase III study of histamine dihydrochloride plus interleukin-2 (IL-2) versus IL-2 alone in patients (pts) with metastatic melanoma (MM). Ann of Oncol. 11(4):1124; 2000
108. 2000 Histamine Dihydrochloride as an Adjuvant to Interleukin-2 (IL-2) Therapy in Metastatic Melanoma: Results of a Multicenter, Randomized, Phase III Trial Cancer Investigation 19(1)
109. 1999 Iatrogenic Swallowing Disorders: Chemotherapy Comprehensive Management of Swallowing Disorders, 1st Edition, Ricardo L. Carrau, MD, FACS and Thomas Murry, PhD (eds), Singular Publishing Group, Inc., pp 125-130
110. 1999 Adjuvant Therapy of Melanoma Cancer Control 6(4):400-403, 1999
111. 1999 Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients with Metastatic Melanoma Journal of Clinical Oncology 17(9):2745-2751
112. 1999 A Phase I and Pharmacokinetic Study of Temozolomide and Cisplatin in Patients with Advanced Solid Malignancies Clinical Cancer Research. 5(7):1629-37
113. 1999 A Phase III Randomized Trial of Dacarbazine and Carboplatin with and without Tamoxifen in the Treatment of Patients with Metastatic Melanoma. Cancer 85(9):1979-1984
114. 1999 Post-Hoc Economic Analysis of the Phase III Comparison of Oral Temozolomide Versus Intravenous Dacarbazine in Metastatic Melanoma. Proc Amer Soc Clin Oncol 18:415a, 1999
115. 1999 A Phase III Multicenter Randomized Trial of DTIC, Cisplatin, BCNU and Tamoxifen Versus DTIC Alone in Patients with Metastatic Melanoma. Proc Amer Soc Clin Oncol 18:536a, 1999
116. 1999 Differential Effect of IFN a-2b on CYP450 Enzyme System: A Potential Issue of IFN toxicity and Its Modulation by Other drugs Proc Amer Soc Clin Oncol 18:539a, 1999
117. 1999 Current Approaches to Advanced and High-Risk Melanoma ASCO Fall Educational Book 1999 pps.83-97
118. 1999 Melanoma Immunotherapeutic Approaches BioDrugs 12(3):193-208; 1999
119. 1999 Adjuvant Chemotherapy in Head and Neck Cancer Hematology/Oncology Clinics of North America 13(4):743-751; 1999
120. 1999 Interferon-a in the Adjuvant Therapy of Melanoma Cancer Investigation 17(1):19-20; 1999
121. 1998 Phase I study of RAD/P53 in patients (pts) with advanced Head and Neck Cancer (HNC). Proc Amer Soc Clin Oncol 17:384a
122. 1998 Plant derived agents Current Cancer Therapeutics, 3rd edition. Kirkwood JM, Lotze MT, Yasko J (eds), Princeton Academic Press, pp. 98-110, 1998
123. 1998 Adjuvant High-Dose Interferon-a therapy in Melanoma Cancer Therapeutics 1(3):178-183, 1998
124. 1998 Adjuvant Interferon Treatment for Melanoma Hematology/ Oncology Clinics of North America, 12(4):823-33; 1998
125. 1998 Adjuvant Therapy of Melanoma Sem in Surg Oncol 14:302-310; 1998
126. 1998 Adjuvant therapy of melanoma Cutaneous Melanoma. (third edition) Charles Balch (ed)
127. 1998 A phase I-II trial of Dacarbazine, Decrescendo IL-2 and IFN Alfa-2b in Metastatic Melanoma Proc Amer Soc Clin Oncol 17:523a,
128. 1998 Pharmacokinetic study of Temozolomide penetration into CSF in a patient with dural melanoma Ann of Oncol 9(4):138, 1998
129. 1998 Stereotactic Radiosurgery for Cerebral Metastatic Melanoma: Factors Affecting Local Disease Control and Survival Int J Radiation Oncology Biol. Phys 42 (3):581-589
130. 1998 Adjuvant High-Dose Interferon-a Therapy in Melanoma: Practical Guidelines. Cancer Therapeutics 1:178-183
131. 1997 Phase I study of temozolomide in combination with interferon Alfa-2B in metastatic malignant melanoma Proc Amer Soc Clin Oncol, 16:491a, 1997
132. 1997 A phase I study of temozolomide combined with cisplatin (CDDP) in patients with advanced cancer Proc Amer Soc Clin Oncol, 16:236a, 1997.
133. 1997 . Docetaxel and carboplatin: a phase I and pharmacokinetic trial for advanced non-hematologic malignancies Proc Amer Soc Clin Oncol 16:220a, 1997
134. 1997 A phase II trial of Thymitaz (AG337 in patients with squamous cell carcinoma of the head and neck Proc Amer Soc Clin Oncol, 16:387a
135. 1996 Cancer screening and diagnosis: Paraneoplastic syndromes Medical Clinics of North America, 80 (1): 173-184
136. 1996 Melanoma: Immunotherapeutic Approaches Adis International Unlimited, 1996
137. 1996 Concurrent Brachytherapy (BT) and carboplatin (CBP), mitomycin - C (M) for locally recurrent squamous cell carcinoma of the head and neck (SCHN): A phase II trial Proc Amer Soc Clin Oncol 15:318, 1996
138. 1996 Plant derived agents Current Cancer Therapeutics, 2nd edition. Kirkwood JM, Lotze MT, Yasko J (eds), Princeton Academic Press, pp. 98-110, 1996
139. 1996 Interferons in melanoma Current Opinion in Oncology 8:167-174
140. 1996 Molecular analysis of atypical (dysplastic) nevi in patients with melanoma Proc Am Soc Clin Oncol 15:433, 1996
141. 1995 A phase I trial of intra-arterial cisplatin (CDDP) with or without embolic occlusion (EO) of the hepatic artery in metastatic ocular melanoma (OM) Proc Am Soc Clin Oncol 14:418, 1995
142. 1995 Potential uses of interferon alfa-2a as adjuvant therapy in cancer Annals of Surgical Oncology 2(4):365-371, 1995
143. 1995 Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma - a phase I study Am J Clin Oncol 18(3):211 - 215
144. 1995 Interferons in Solid Tumors Journal of Associated Physicians of India 3:38 - 43
145. 1994 Phase Ib trial of murine monoclonal R24 anti-GD3 antibody in 37 patient with metastatic melanoma Proc Am Assoc Cancer Res 1994
146. 1994 Plant derived agents Current Cancer Therapeutics, 1st edition. Kirkwood JM, Lotze MT, Yasko J (eds), Princeton Academic Press, pp. 74-81, 1994
147. 1994 Interferons in the therapy of solid tumors Oncology (Karger), 51:129, 1994
148. 1994 The Sznol and Parkinson article reviewed Oncology 8: 67, 1994
149. 1993 Systemic Therapy of melanoma, principles & practice of oncology (PPO) updates Devita VT, Hellman S, Rosenberg R, (editors), Vol. 7, No 8, August 1993
150. 1992 A double-blind phase I, placebo-controlled study of the safety, pharmacokinetics and immunological effect of single, ascending doses of 7-allyl-8-oxyguanosinein patients with advanced cancer Pro Am Assoc Cancer Res 33:263, 1992 (abstr).
151. 1992 A phase I study of combination carboplatin and cisplatin in patients with metastatic cancer Proc Am Soc Clin Oncol 10:129, 1992
152. 1992 Pharmacokinetic study of combination carboplatin and cisplatin in patients with metastatic cancer Proc Am Assoc Cancer Res 33:263, 1992 (abstr).
153. 1991 Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma - a phase I study Proc Am Assoc Cancer Res 32:195, 1991 (abstr
154. 1991 Phase II study of Interferon-alfa in locally recurrent or metastatic head and neck cancer. Result of ECOG trial PZ-386 Proc Am Soc Clin Oncol 10:205, 1991 (abstr).
155. 1990 Continuous cyclophosphamide, doxorubicin, vincristine and prednisolone: A new, innovative protocol for diffuse aggressive lymphomas Cancer 65:1704-1710
156. 1989 Corticosteroid-responsive pure red cell aplasia in rheumatoid arthritis and its association with pregnancy: A case report American Journal of Hematology 31:58-61
157. 1989 Cisplatin-based chemotherapy in advanced ovarian cancer: Initial experience in an Indian set-up Ind J Cancer 26:85-91
158. 1989 None Melanoma: Translational Research and Emerging Therapies, (Editors), Informa Publications


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.